Hims & Hers Health, Inc. (HIMS.US) 2026年第二季度业绩电话会
文章语言：
简
繁
EN
Share
Minutes
原文
会议摘要
The company, focusing on AI integration for personalized health solutions, international expansion, and strategic investments, forecasts significant revenue growth to $6.5 billion by 2030. Achieving this involves enhancing customer experience, reducing costs, and expanding into new markets and health categories, aiming to lead in accessible global healthcare.
会议速览
Investor Relations Update: Earnings Release, Financial Measures, and Webcast InformationA presentation on earnings, non-GAAP financial measures, and related reconciliation tables is highlighted. The content directs attention to the company's investor relations website for further details and mentions an archived webcast available for 12 months.
Revolutionizing Global Healthcare: AI Integration and Customer Trust in Health ServicesThe company highlights its advancements in AI and technology, emphasizing the creation of a unified health experience. With a global subscriber base nearing 3 million, the focus is on delivering personalized care, from initial health inquiries to ongoing treatment and follow-up. The narrative underscores the importance of customer trust, earned over nine years, and the commitment to providing accessible, high-quality care worldwide.
Revolutionizing Healthcare: AI-Driven Personalized Care ExperienceThe company is leveraging AI to transform traditional telehealth, creating a unified, personalized care platform that enhances customer engagement, reduces non-clinical tasks, and improves clinical outcomes, positioning itself as a leader in health technology.
Expanding Healthcare Solutions: Hims' Focus on Complex Conditions and PeptidesHims is leveraging its infrastructure to offer tailored solutions for complex health challenges, such as testosterone treatment, and is developing a best-in-class peptides experience, including FDA-recommended peptides, to meet surging market demand with safe and verified supply chains.
Expanding Global Scale and Customer-Centric Healthcare Model for Enhanced Access and EfficiencyThe company has become the leading global consumer health platform through strategic acquisitions and operational growth, offering a personalized, accessible, and effective weight management experience worldwide. Leveraging its scale and technology investments, it aims to remove middle layers in healthcare, directly connecting innovators with consumers, and expanding partnerships to deliver affordable, comprehensive health solutions.
Expanding Global Health Services: Accelerating Growth and Proving Comprehensive Care at ScaleA world-class health experience is being built at global scale with a focus on expanding customer relationships, revenue growth, and strategic investments in specialties like weight loss and sexual health. Domestic operations saw accelerated revenue growth, driven by a pivot to branded weight loss products, while international expansion, including the acquisition of Eucalyptus, significantly boosted international revenue. The company is committed to leveraging data, infrastructure, and economies of scale to provide more accessible and comprehensive health solutions for millions of consumers globally.
Expanding Revenue Footprint & Strategic Investments Drive Long-Term GrowthThe dialogue highlights significant revenue diversification across specialties and geographies, with plans to scale weight loss offerings and international markets. Despite gross margin compression due to strategic investments, the company aims for robust EBITDA and cash flow generation, leveraging its scale, infrastructure, and balance sheet for long-term platform value.
Investments in AI and Engineering Yield Cost Savings and Efficiency Gains in Health ServicesStrategic investments in AI and engineering have led to significant cost savings and operational efficiencies, with AI initiatives reducing non-clinical tasks by 50%, improving subscriber engagement, and lowering cancellations. Marketing spend efficiency has increased, benefiting from organic cross-selling and brand investments, while collaborations with pharmaceutical companies and global brand moments enhance consumer trust and platform awareness.
Navigating Financial Challenges and Growth Opportunities with Strategic Investments and Liquidity SolutionsDespite a GAAP net income loss of 86 million, attributed to acquisition, restructuring, and legal costs, the company leverages its robust cash flow, a 400 million receivables facility, and a convertible debt offering to bolster its balance sheet. Anticipating a return to free cash flow generation in H2, the company remains poised to invest strategically, capitalizing on growth while maintaining financial flexibility.
Investing in AI, Weight Loss, and International Expansion to Achieve 2030 Financial AmbitionsThe dialogue highlights strategic investments in AI to enhance user experience and reduce costs, with plans to apply savings towards making weight loss treatments more accessible. It also emphasizes aggressive international market expansion, aiming to lead in health and wellness services, and continuous development of new, higher-complexity health offerings.
Outlook for Revenue and EBITDA Growth, Highlighting Global Expansion and Health Platform AdvancementsThe dialogue outlines a strategic financial outlook with significant revenue and EBITDA growth projections, emphasizing the company's global expansion, investment in high-value health services, and commitment to enhancing consumer health experiences. It highlights the impact of scaling weight loss offerings and international markets, along with the anticipated increase in adjusted EBITDA margins, reinforcing confidence in achieving long-term ambitions of substantial revenue and EBITDA targets by 2030.
Strategies for Peptide Market Entry and AI-Driven Health Ecosystem DevelopmentThe dialogue covers preparations for entering the peptide market following FDA guidance, emphasizing rapid compliance and launch readiness. It also outlines plans to integrate AI with health data for proactive care, aiming to democratize concierge-level health services. Additionally, it highlights the successful partnership with Novo Nordisk, focusing on retention, engagement, and expanding access to innovative treatments.
Expanding Specialty Areas and Regulatory Hurdles in International MarketsThe dialogue discusses the integration of acquisitions in international markets, highlighting success in weight loss and digital health, with potential expansion into testosterone replacement, menopause therapy, and peptides. It also addresses the waiting period for FDA guidance before selling approved peptides, emphasizing the importance of final rulemaking.
Q&A on Eucalyptus Impact, US Revenue Acceleration, and International Expansion StrategiesThe dialogue discusses the effect of Eucalyptus contributions on EBITDA, anticipated acceleration in US revenue due to enhanced weight loss offerings, and strategic reinvestment in international markets to secure leadership positions, all reflecting the company's guide for the back half of the year.
AI-Driven Expansion and Category Prioritization in Health ServicesThe dialogue highlights the strategic implementation of AI in enhancing patient engagement and operational efficiency within health services. It emphasizes the successful deployment of AI in the women's weight loss business, showcasing a significant reduction in non-clinical tasks and an increase in patient interaction. The strategy involves leveraging high patient engagement to inform and accelerate the expansion into new health categories, prioritized based on patient needs and market overlap, with a focus on metabolic health, hormonal health, and sleep recovery. The approach aims to utilize existing patient populations for clearer targeting and comprehensive care bridging, ensuring informed and rapid market entry for new services.
Analyzing Subscription Growth, Business Model Evolution, and Category ExpansionThe dialogue explores the recent surge in subscriptions, attributing growth to business model enhancements and new therapy offerings. It highlights the strategic partnership with large drug companies, the reacceleration in men's hormonal health, and plans for international expansion, indicating a balanced approach to metabolic and traditional healthcare services.
Revenue Acceleration Driven by Domestic Growth and International InvestmentEucalyptus revenue contributed significantly to the second quarter, with domestic growth accelerating due to successful offerings and specialties. This success provided resources for further investment in international markets.
Eucalyptus Business Margin Update and Long-Term Financial StrategyDiscussion covers Eucalyptus' current near-breakeven status and future margin expectations, emphasizing strategic investment and cash flow generation for long-term growth.
要点回答
Q：What are the three key areas driving Hims and Hers's continued growth?
A：The three key areas driving Hims and Hers's continued growth are their investment in AI and technology leading to a unique health experience, their world-class infrastructure that supports a broad spectrum of customer needs and allows for faster, larger-scale expansion into complex categories, and their global reach, which, paired with technology and infrastructure, creates a platform for high-quality care that is both personal and widely accessible.
Q：Why is investing in AI so critical for Hims and Hers?
A：Investing in AI is critical for Hims and Hers because it enables the company to deliver a unified, AI-native health experience that is unique in the market. This approach allows Hims and Hers to support customers through their entire health journey, from initial questions to clinical treatment and follow-up care, creating a closed-loop relationship. The company believes that this end-to-end, personalized care, supported by scale, customer trust, and a strong evidence base, differentiates Hims and Hers and is essential for providing high-quality care.
Q：What was the impact of Hims and Hers's AI rollout for weight loss customers?
A：The impact of Hims and Hers's AI rollout for weight loss customers was significant, with those using the new care experience sending three times as many messages on the platform. The AI answered 80% of their questions, which supported their treatment journey. As a result, non-clinical tasks were reduced by nearly 50% for the care teams. Engaged, intentional conversations between customers and AI helped to identify clinical challenges such as dosage adjustments and treatment changes more quickly, allowing for earlier interventions and keeping customers on track.
Q：What differentiates Hims and Hers's AI approach from others in the market?
A：Hims and Hers's AI approach is differentiated from others in the market by its clinical grounding and the fact that it is an agentic customer support experience, developed with a team of medical experts. The AI is bound by clinical protocols and guidelines, ensuring that interactions are traceable and auditable. Unlike other AI models, Hims and Hers's is designed to work in conjunction with clinical decision-making, elevating rather than replacing providers, and is focused on delivering a complete health experience rather than just a commodity AI service.
Q：How does Hims and Hers plan to further integrate AI into the customer experience?
A：Hims and Hers plans to further integrate AI into the customer experience by continuing to develop AI talent, opening an AI R&D lab in Menlo Park, and adding new AI professionals to the team. These moves are part of a strategy to bring the AI experience to all customers and to accelerate investment in AI integration across the customer journey.
Q：How does tracking outcomes influence Hims and Hers's ability to improve the health experience for its users?
A：Tracking outcomes is critical to Hims and Hers's ability to improve the health experience for its users because it enables the company to operate a closed-loop system that includes intake, treatment, follow-up, and outcome evaluation at a large scale. This system allows Hims and Hers to learn from all stages of the process, leading to an ongoing cycle of improvement. As the company rolls out this new experience to more customers, it expects to improve the quality and depth of care accessed on the platform, which will in turn keep customers longer and attract new ones.
Q：What are Dr Nan vija Mori's credentials and how will they contribute to Hims?
A：Dr Nan vija Mori has over a decade of clinical experience in internal medicine, primary care, and longevity, which will be critical for building and expanding Hims' offerings in categories like hormonal health, longevity, and peptide therapy. His participation demonstrated his trusted voice among industry leaders and regulators.
Q：How does Hims plan to proceed with FDA decisions regarding the six peptides from the recent PCAC hearing?
A：Hims is conducting validation and stability testing on APIs for the six peptides developed in their Menlo Park facility. If the FDA allows them for compounding, they plan to bring them to the market with a safe, verified supply chain. Until then, they will offer access to already allowed peptides with safe and well-established websites, including solutions like sermorelin, glutathione, and NAD+ before the end of the year.
Q：What is the significance of Hims' acquisition of Eucalyptus and its impact on their international presence?
A：The acquisition of Eucalyptus, the largest in Hims' history, has made Hims the leading global consumer health platform. This acquisition also extended Hims' presence into three international markets outside the US, all operating above a $100 million annual run rate. It signifies Hims' comprehensive experience now available to customers worldwide.
Q：How does Hims plan to use the consumer-centric model to its advantage in the healthcare industry?
A：Hims is adopting the consumer-centric model to transform healthcare by removing middle layers and ensuring innovators can directly reach consumers, which they believe makes them structurally more efficient than others in healthcare. This model is evidenced by their scale, technology, and infrastructure investments, allowing them to offer comprehensive personal health experiences at affordable prices.
Q：What is Hims' strategic approach to growth and value delivery?
A：Hims' strategic approach to growth and value delivery includes leveraging their leadership position to create sticky relationships with millions of customers worldwide, focusing on a profitable business model, and deepening customer relationships. They aim to deliver more value to customers at better prices, and they are proving that they can offer a world-class health experience at global scale at a reasonable price.
Q：What are the key financial highlights from Hims' second quarter report?
A：In the second quarter, Hims experienced nearly a 40% year-over-year revenue growth to over $753 million, with 300,000 net new subscribers added. Domestic revenue growth accelerated to 16% year over year, with the branded weight loss product assortment expansion being a key driver. The company also saw international revenue increase over 17-fold year over year to $131 million, bolstered by the Eucalyptus acquisition. Hims is on track to deliver north of $1 billion in revenue for the year, with new specialties contributing to growth.
Q：What is Hims' adjusted EBITDA margin and how does it compare to the previous quarter?
A：Hims' adjusted EBITDA for the second quarter was $60 million, representing an 8% adjusted EBITDA margin, which was a one-point improvement from the previous quarter. This reflects operating leverage that more than offset gross margin headwinds from the revenue mix shift towards weight loss and the revenue contributions from the company's international business.
Q：What are the signs of the impact of AI on the support teams and subscriber experience?
A：The successful pilots have demonstrated that AI can drive a 50% reduction in non-clinical tasks handled by support teams. Early signs indicate stronger engagement and lower cancellations for participating subscribers, which suggests an improved subscriber experience and potential cost savings as these capabilities mature.
Q：How are collaborations with pharmaceutical innovators like Novo Nordics creating marketing opportunities?
A：Collaborations with pharmaceutical innovators like Novo Nordics are resulting in real marketing gains. Breakthrough treatments are drawing consumer attention to weight loss categories, and the company's platform makes health simple, personal, and approachable, turning consumer curiosity into new care relationships efficiently.
Q：What actions have been taken to ensure the company's balance sheet is not a hindrance to growth opportunities?
A：To ensure the balance sheet doesn't limit growth opportunities, the company has established a 400 million receivables facility and completed a convertible debt offering for over 400 million. These actions provide an efficient mechanism for converting accounts receivable into cash and reinforce the balance sheet.
Q：What are the core strategic growth levers being focused on?
A：The core strategic growth levers include using technology to elevate the quality of care, expanding into new specialties, broadening access to personalized care, leveraging partnerships for health service curation, and expanding internationally.
Q：What are the benefits of successful AI efforts in the weight loss segment?
A：Successful AI efforts could lead to lower prices and additional tools for weight loss subscribers by the end of the year. This aligns with the playbook used in other specialties to steadily lower prices, expand the addressable market, improve retention, and drive stronger LTV and margin expansion.
Q：What is the plan for AI investments and how will they improve the consumer experience?
A：The plan involves accelerating investments in technology and AI to improve the consumer experience, resulting in a reduction in cancellations and a more consistent, personalized experience. AI investments are expected to pay back within 12 to 18 months and provide structural advantages for reinvestment in growth areas and international markets.
Q：How will AI efficiency improvements be utilized in the international business?
A：Efficiencies from AI will be redeployed to accelerate growth within the international business. The company plans to invest aggressively in markets like Australia, Japan, Canada, Germany, and the UK to build category leadership and category expansion, which will help to scale the business and potentially turn these markets into meaningful profit centers.
Q：What is the outlook for the remainder of the year in terms of revenue and Adjusted EBITDA?
A：The company is anticipating revenue between 880 to 900 million in the third quarter, representing a year-over-year increase of approximately 47% to 50%. The expected Adjusted EBITDA is between 75 to 95 million. For the full year, the revenue outlook is raised to 3.1 to 3.3 billion, with an expectation of Adjusted EBITDA between 275 and 325 million.
Q：What are the updates on API manufacturing in Menlo Park and the expected timeline for FDA decision-making?
A：The company has committed to manufacturing APIs in the US at an API facility in Menlo Park, which is considered rare and they are likely the only company capable of doing so. They are in the process of conducting stability and validation testing for BPC 1 57. The timeline for FDA decision-making was not specified in the transcript.
Q：Is there a plan to integrate different types of health data for a real-time health score and what is the status of this initiative?
A：The company has a plan to bring together various elements of a person's health, including wearable data, lab testing data, preventative screening, and genetics, to provide an ecosystem of health services. This initiative aligns with a vision of offering a 360-degree view of health through AI and has been described as a powerful freemium offering. The team is actively building toward this, and it is considered to be the vision for the future of the service offered by the company.
Q：What progress has been made in the partnership with Novo Nordisk and how is retention and engagement in the branded cohorts?
A：The partnership with Novo Nordisk has been successful in terms of volume, with the Will Gobi pill having a strong launch and the company becoming one of the largest players in helping people access this pill. There are strong domestic and international relationships with Novo Nordisk. Regarding retention and engagement in the branded cohorts, they have performed better than historical retention rates across other products, and the company is looking at ways to deepen the relationship with Novo Nordisk.
Q：What are the plans for expanding the assortment in international markets and the potential areas for growth, especially for Eucalyptus?
A：Eucalyptus has successfully built dominance in the UK, Australia, Germany, Japan, and Canada in the weight loss category and is a leading digital health provider in those markets. There is potential to expand the assortment, including specialties like testosterone replacement therapy, menopause therapy, dermatology categories, and peptide therapies in some markets. Eucalyptus is well-equipped to deliver on opportunities to bring these categories into at least five or six markets overseas using their current commercial strategy.
Q：What is the company's operating model regarding FDA rulemaking for the sale of peptides?
A：The company's current operating model is to wait for full and final rulemaking from the FDA before bringing the products to market. They believe it is essential for the FDA to complete this process before they can effectively bring the products to market, although the exact timeline for FDA rulemaking was not specified in the transcript.
Q：How is Eucalyptus contributing to the back half of the year in terms of EBITDA growth and acceleration in revenue?
A：Eucalyptus is expected to contribute to greater acceleration on both revenue and EBITDA in the US during the back half of the year. The transcript provides a catalyst behind the expected acceleration but does not quantify the exact impact on EBITDA growth or the acceleration in revenue for the back half of the year.
Q：What are the driving forces behind the monthly cadence switch and its effects on revenue and EBITDA?
A：The monthly cadence switch is attributed to the branded products' cohort stock increase due to greater tenure on the platform. This results in more revenue and EBITDA, and the effect is expected to compound in Q3 and Q4.
Q：What are the anticipated benefits of efficiencies across the portfolio and the reinvestment of savings?
A：Efficiencies across the portfolio, primarily in the U.S. and early savings from AI, are expected to be reinvested into enhancing the weight experience, making price points more accessible, and increasing platform stickiness, as well as in expanding the company's presence in attractive international markets like the UK, Germany, and Canada.
Q：How is the company planning to use the savings from AI in its operations?
A：The company plans to use the savings from AI to invest in creating a more immersive weight experience for consumers, making price points more accessible, and in developing tools to increase platform stickiness. Additionally, these savings will be deployed in international markets to adhere to the company's capital allocation standards and to achieve a one-year or less break-even period.
Q：Why was the women's weight loss business chosen as the starting point for AI adoption?
A：The women's weight loss business was chosen as the starting point for AI adoption because it is one of the highest engagement parts of the business, and there is significant complexity in the category, including aspects like injection fears, dosing regimens, and side effect mitigation.
Q：What criteria is the company using to prioritize new product categories?
A：The company is prioritizing new product categories based on feedback from nearly 3 million subscribers regarding where the business and clinical needs exist. The strategy includes lab testing infrastructure for various categories such as metabolic and hormonal health, and sleep and recovery, which are areas showing significant patient interest.
Q：What is the recent growth attributed to in the company's weight loss business?
A：Recent growth in the company's weight loss business is attributed to expanding the offerings on the weight loss side to include new therapies and forming mutually beneficial relationships with large drug and biotech companies. Additionally, the reacceleration across categories, particularly the men's hormonal business, has contributed to this growth.
Q：What is the recent growth attributed to in the company's core HEMS business?
A：The recent growth in the company's core HEMS business is attributed to the acceleration of domestic revenue, especially in the weight category, and the continued success and scaling of new initiatives such as the low testosterone offering and other specialties.
Q：What is the current break-even status of Eucalyptus and what are the expectations for its future performance?
A：Eucalyptus is currently running at breakeven to moderate losses. The company expects it to be near or at breakeven as well, with plans to expand into international markets in a thoughtful way as the domestic market strengthens.
Q：Can you clarify the long-term margin profile and expected trajectory?
A：The company is focused on generating strong free cash flow and EBITDA dollar amounts in the short term. While it is not prepared to discuss 2027 margins specifically, it does expect to maintain strong cash flow generation and EBITDA dollar amounts as it continues to lean and invest aggressively in its business. The cohort stacking in the weight loss category and benefits from new specialties are factors supporting this strategy.
